Alzheimer’s researchers — or the public relations machines breathlessly trumpeting their work — should chill out. I see so much of this type of Alzheimer’s news that it’s hard to...
Researchers receive $47M grant to study Alzheimer’s disease
By
John Roszkowski
Sep 26, 2022
Researchers from the University of California, Irvine have been awarded a $47 million grant from the National Institute on Aging to develop animal models to study the biology behind Alzheimer’s disease.
Humanizing and changing dementia care
By
Karen Love and Jackie Pinkowitz
Aug 06, 2012
A new effort known as the Dementia Initiative germinated from the belief that there is a moral and ethical societal imperative to view and understand people living with dementia as whole beings, and not...
‘Surprising’ study results find moderate exercise may worsen Alzheimer’s
By
Kimberly Marselas
May 18, 2018
Moderate exercise, long thought to be a tool in the battle against Alzheimer’s disease, may actually hasten symptoms if done regularly after diagnosis, a new study suggests.
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
Vigorous exercise may guard against death from Alzheimer’s disease
By
Kristen Fischer
Dec 18, 2023
Engaging in vigorous activity compared to moderate exercise may lower the rate of dying from Alzheimer’s disease, according to a new study. The study was published in the December issue of The Lancet...
Not all older adults can get monoclonal antibodies for Alzheimer’s disease, study finds
By
Kristen Fischer
Sep 22, 2023
Even though newer monoclonal antibodies are available for Alzheimer’s disease, there are limits on the number of older adults who can receive them, a recent study published in Neurology finds.
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
To save itself, might Medicare deny coverage of controversial new Alzheimer’s drug?
By
Kimberly Marselas
Jun 28, 2021
The true price to administer aducanumab — a controversial new Alzheimer’s treatment — may actually be closer to $100,000 annually than other, lower estimates and is just one reason the Centers for...